TY - JOUR T1 - 2022-RA-1474-ESGO Traditional systemic treatment options in advance low grade serous ovarian cancer after successful cytoreduction. A systematic review and meta-analysis JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A341 LP - A341 DO - 10.1136/ijgc-2022-ESGO.725 VL - 32 IS - Suppl 2 AU - Rosa Montero Macías AU - Pascal Rigolet AU - Elie Mikhael AU - Jonathan Krell AU - Vincent Villefranque AU - Fabrice Lecuru AU - Christina Fotopoulou Y1 - 2022/10/01 UR - http://ijgc.bmj.com/content/32/Suppl_2/A341.1.abstract N2 - Introduction/Background We performed a systematic literature review and a subsequent meta-analysis to compare traditional ie. antihormonal and cytotoxic treatment options in advance Low Grade Serous Ovarian Cancer (LGSOC).Methodology We conducted a systematic literature review in MEDBASE and MEDLINE between September 2000 and June 2021 for women who received cytotoxic chemotherapy and/or antihormonal treatment after primary cytoreduction due to stage II-IV LGSOC and also at relapse. PFS and OS were calculated depending on the type of their adjuvant treatment. For each endpoint in the meta-analysis, pooled HR was calculated using the random effect model with the inverse variance weighted method. Only primary patients were included in the subsequent meta-analysis due to the small number of studies in the relapsed setting.Results Five eligible 1st line studies were included. Systemic chemotherapy failed to provide a significant OS benefit when compared to no systemic treatment (pooled HR = 1.01, 95% CI [0.79, 1.29]) after successful cytoreduction.Moreover, systemic chemotherapy followed by antihormonal treatment also did not result to a significant PFS or OS benefit when compared to systemic chemotherapy alone (for PSF: pooled HR=0.59, 95% CI [0.33, 1.04]; for OS: pooled HR=0.83, 95% CI [0.50–1.39]).There were insufficient data from studies in the recurrent setting to allow their inclusion in the meta-analysis.Abstract 2022-RA-1474-ESGO Figure 1 Conclusion In this meta-analysis, we failed to identify a traditional cytotoxic or antihormonal systemic treatment option that was associated with a significant OS or PFS benefit when administered following successful cytoreduction for advanced LGSOC. Prospective randomised studies are urgently warranted to define optimal adjuvant options in this challenging disease. ER -